Search Results

Parkinson’s Disease: A Mini-Review of Clinical Pharmacology. 2006 . (4)         Garcia-Borreguero, D. 2018 , 839 , 40–46. https://doi.org/10.1016/j.ejphar.2018.09.008 . (8)         Rinken, A.; Lavogina, D. D.; Hanada, K.; Pagano, R. E.; Miller, L. J. -J.; Kopanchuk, S.; Laasfeld, T.; Weinhart, M.; Schollmeyer, D.; Betschart, M.

Highlights: • The Foundry Arrives : R&D meets biotech with real-world acceleration, strategic consulting

currents GPCR Binders, Drugs, and more LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine

endosomes and other organelles. eLife. 2024 Nov 8; 13:RP97033. doi: 10.7554/eLife.97033.3   Maurel D,

Comparative evaluation of biased agonists Sarcosine1 , d-Alanine8 -Angiotensin (Ang) II (SD Ang II) and GPCRs in Oncology and Immunology LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine

one sustained curiosity thread involved a protein released by alpha cells in the pancreas: Vitamin D

Career opportunities:  Senior Scientist, Phage Display | Manager, CMC Management | Translational R&D

Miranda-Pastoriza D, Bernárdez R, Azuaje J, Prieto-Díaz R, Majellaro M, Tamhankar AV, Koenekoop L, González

is strategic, method-proven insight for discovery teams, pharmacologists refining core skills, and R&D

startup environments Read Maria Majellaro's Full Recap ➤ Lab Leadership Without Ego: A Model for R&D

Hilger, D., et al., Structural insights into differences in G protein activation by family A and family

For Hodson, that moment came with a protein he’d been tracking for a decade: vitamin D binding protein

GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr.

do: bring four decades of frontline discovery insight straight to discovery-phase scientists and R&D

Every R&D team is under the same pressure: deliver validated targets, clean pharmacology, and translatable

on Smooth operator(s): dialing up and down neurotransmitter responses by G-protein regulators András D

Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D

GPCR Activation and Signaling Statins inhibit protein kinase D (PKD) activation in intestinal cells and

Structural and Molecular Insights into GPCR Function Endogenous l- to d-amino acid residue isomerization

Wootten, D., et al., The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased

Jurado, S., D. Goswami, Y. Zhang, A.J.M. Molina, T.C. Südhof, and R.C. Malenka. 2013.

G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation Chiara D

Scribble scrambles parathyroid hormone receptor interactions to regulate phosphate and vitamin D homeostasis

First Protein Structures in PDB, Advances Lupus Therapy Research Structure Therapeutics Receives R&D

from September 30th to October 6th, 2024 Industry News Nxera Pharma appoints experienced commercial R&D

Wang, D., The essential role of G protein-coupled receptor (GPCR) signaling in regulating T cell immunity

This Week’s Highlights: G protein-coupled receptor (GPCR) pharmacogenomics Miles D Thompson , David

Statins inhibit protein kinase D (PKD) activation in intestinal cells and prevent PKD1-induced growth

Araç, D., et al., A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis

CRS2), which will trigger conformational changes that ultimately lead to receptor activation (Scholten D